Scepticism continues to shroud UCB's future
This article was originally published in Scrip
Executive Summary
Piper Jaffray is the latest group of analysts to share concerns over UCB after downgrading their recommendation for the Belgian company. The analysts lowered their guidance from neutral to sell after noting that Keppra's (levatiracetam) rate of generic erosion remains a key sensitivity.